海外の治験の状況「COVID-19」での検索結果
18件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Réponse au traitement néoadjuvant par l'anti-aromatase anastrozole et l'anti-oestrogène pur fulvestrant : étude de phase II randomisée chez des patientes ménopausées atteintes d'un cancer du sein non métastatique hormono-sensible et étude exploratoire de la signature moléculaire de la réponse. - HORGEN
- Cancer du sein non métastatique hormono-sensible. MedDRA version: 9.1 Level: LLT Classification code 10006188 Term: Breast cancer female NOS
- France
- 2007-08-23
Authorised
- A study for patients with advanced breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.
- Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy. MedDRA version: 16.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2013-10-18
Authorised
- Letrozole adjuvant therapy after tamoxifen. Study of gene CYP19 correlation with letrozole efficacy in postmenopausal early breast cancer patients
- Patients selection to give letrozole for 5 years after 5 years of tamoxifen as adjuvant hormonal therapy MedDRA version: 14.1 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2005-09-02
Authorised
- Optimalising the Androgen-Oestrogen Balance in Testosterone Substituted Hypogonadal Men by Aromatase Inhibition.
- Men with hypogonadotropic hypogonadism treated with testosterone substitution
- Netherlands
- 2007-01-12
Authorised
- Clinical study in children 1-19 years on maintenance therapy for acute lymphoblastic leukemia
- Pediatric acute lymphoblastic leukemia;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Finland
- 2018-05-16
Authorised
- A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequate Response to Methotrexate. Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 19-Dec-2007); Revised Protocol 01, incorporating administrative letter 01 and amendment 03 (version 1.0, dated 12-Mar-2008)
- subjects with rheumatoid arthritis (RA) who are on background therapy with methotrexate (MTX) MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis
- Czech Republic, France, Spain
- 2008-04-15
Authorised
- A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to adults aged 66 years and older compared to Fluarix™ administered to adults aged 19-43 years and 66 years and older, who previously participated in the 111737 study. - FLU NG-039 EXT: FLU-AS25-025 Y2
- Immunization against influenza in male and female subjects aged 19-43 years and 66 years or older.
- Germany, Netherlands, Sweden
- 2009-07-02
Authorised
- Phase IIIb Multicenter, Single Arm, Open-label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance with Atazanavir/ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression. Revised Protocol 01, incorporating Protocol Amendment 01 (Version 1.0, Date 19-Jan-2007). Estudio piloto de fase IIIb, de un solo brazo, abierto y multicéntrico, para evaluar la eficacia y la seguridad del mantenimiento con atazanavir/ritonavir en monoterapia en pacientes infectados por el VIH que muestren supresión virológica. Protocolo Revisado 01, que incorpora la enmienda 01 al protocolo (v 1.0 de fecha 19-enero-2007). - OREY
- HIV-Infected Patients Evidencing Virologic Suppression Pacientes infectados de VIH, con supresión virológica evidente
- Spain
- 2010-03-12
Authorised
- Essai randomisé, en double aveugle, chez les femmes ménopausées ayant un cancer du sein RE+ comparant deux traitements néo-adjuvants : un anti-aromatase (Letrozole) VS un SERM (Tamoxifène). Effet sur des variables biologiques intermédiaires prédictives de la réponse au traitement
- Le cancer du sein est le cancer féminin le plus fréquent en Europe représentant 28% de tous les cancers féminins. Son incidence y est de l’ordre de 70 pour 100 000 femmes. Sa fréquence est stable (une femme sur 10 actuellement). Il est responsable de 20% de la mortalité par cancer chez la femme mais ce taux commence à se stabiliser dans un certain nombre de pays européens (Hermon C, 1996). MedDRA version: 9.1 Level: LLT Classification code 10006187 Term: Breast cancer
- France
- 2010-08-19
Authorised
- A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE). And Pharmacogenetics Blood Sample Amendment Number 1 - Site Specific (Version 2.0, Date 19-Jan-07).
- IMMUNOSUPPRESSION FOR DISEASE, NOS MedDRA version: 9.1 Level: LLT Classification code 10025139 Term: Lupus erythematosus systemic
- Belgium, France, United Kingdom
- 2007-03-26